Nanox.AI vs Riverain Technologies (2026)
Both work on chest and body computed tomography and they answer different questions. Nanox mines scans taken for unrelated reasons, surfacing coronary calcium and vertebral fractures nobody ordered the scan to look for, with a clearance portfolio built over years and a listed parent behind it. Riverain suppresses the vessels so nodules that vasculature was hiding become visible, which changes what the radiologist sees rather than adding a list of what the model found. For a lung program Riverain is aimed at the actual reason nodules get missed. For a population health program Nanox is finding disease nobody was looking for, and generating a follow up obligation the health system pays for, which should be priced alongside the license.
- Its strategy is opportunistic population health, mining scans taken for other reasons to surface findings including vertebral fractures and coronary calcium.
- A deep clearance portfolio built over years across several anatomical findings, with a listed parent whose filings describe the business.
- For a population health program, finding disease nobody was looking for is the entire proposition.
- Vessel suppression addresses a specific reason nodules are missed rather than adding another findings list.
- Long established thoracic focus means the products have been in clinical use across several generations of scanner and protocol change.
- For a lung nodule program, changing what the reader sees is a different intervention from flagging what the model found.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Nanox.AI and Riverain Technologies are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Nanox.AI | Riverain Technologies |
|---|---|---|
| Primary category | Radiology & Imaging AI | Radiology & Imaging AI |
| Founded | 2014 | 2000 |
| Headquarters | Neve Ilan, Israel | Miamisburg, Ohio, United States |
| Website | nanox.vision | riveraintech.com |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
Riverain Technologies
-
EHR / interoperability
Riverain Technologies made its ClearRead chest imaging AI available through RapidAI's Enterprise Platform, delivered over Rapid Edge Cloud and inside the Rapid Navigator Pro radiology workflow.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Imaging AI business of Nasdaq listed Nano-X Imaging, formerly Zebra Medical Vision, acquired in November 2021. Its solutions analyze CT scans already acquired for other reasons to surface undiagnosed chronic disease: HealthOST for vertebral height loss and bone mineral density, HealthCCSng for coronary artery calcium on non gated chest CT, and HealthFLD for liver density in fatty liver disease.
Source: AI Health Index, August 2026
Ohio based company whose ClearRead software applies AI to chest CT and chest radiographs. ClearRead CT produces a vessel suppressed series with nodule detection marks, cleared by the FDA in 2016 (K161201) as an aid to the radiologist for pulmonary nodules on chest CT in an asymptomatic population, and extends to coronary artery calcium scoring (K242188, 2024).
Source: AI Health Index, August 2026
Questions buyers ask
How do Nanox.AI and Riverain Technologies work with the EHR?
For Nanox.AI, the AI page describes integration with PACS, record and reporting systems, and record integration to streamline patient care, and names Corewell Health, Atlantic Health System, Jefferson Einstein Hospital, Rabin Medical Center and NHS hospitals as users. The HealthVCF summary describes findings shown in a standalone worklist application.
With Riverain Technologies, the 510(k) summaries describe delivery through the same DICOM network interface that supplies the CT series. The home page displays the names of health systems including the VA, Cleveland Clinic, Duke, Cedars-Sinai, Michigan Medicine and University Hospital Zurich, and reports more than 400 customer locations. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How are Nanox.AI and Riverain Technologies priced and sold?
In Nanox.AI's case, the parent, a Nasdaq listed company, describes its business model in securities filings, including software as a service billing and a pay per scan model for its imaging hardware. Whether the AI solutions are licensed per scan, per site or per population is not stated, and the answer changes the cost of running a screening program across a whole archive.
For Riverain Technologies, one route to buy is public: ClearRead CT is listed as an application in the Sectra Amplifier Marketplace, the application store for Sectra's PACS, with its integration and regulatory details and no price or licensing terms. The company's home page gives no licensing basis, whether per site, per study or across a health network. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How do Nanox.AI and Riverain Technologies handle patient data?
With Nanox.AI, the solutions read CT studies acquired for unrelated reasons, at archive scale, so most patients whose scans are analyzed will not know a second analysis occurred. There is no published retention period, de identification standard or statement on whether analyzed imaging trains the models.
In Riverain Technologies' case, the K161201 summary describes a postprocessing application that generates a secondary series from the lung CT; where that processing runs, what is retained afterward, whether customer studies are used to train or improve the models, and whether any de identification is applied are not stated. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Which settings and specialties do Nanox.AI and Riverain Technologies cover?
For Nanox.AI, the liver solution's validation is not described on the AI page.
With Riverain Technologies, the nodule detection clearance (K161201) covers chest CT in an asymptomatic population with both lungs in the field of view, supported by a multi reader study, so use on diagnostic chest CT in symptomatic patients falls outside the indication as summarized. Calcium scoring (K242188) and pneumothorax (K213566) are cleared; radiograph nodule detection has no US clearance stated. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Opportunistic detection creates a duty to act whose cost falls on the health system rather than the vendor, since surfaced findings generate follow up imaging, patient notification and an incidental finding pathway, and that should be priced alongside the license. Nanox publishes no health privacy commitment, data governance framework or subgroup analysis for a product designed to run across whole populations. Neither publishes pricing, and neither publishes performance on the scanner mix and protocols a given department actually uses.